NICE has published draft guidance restricting use of antibiotics in patients with chronic obstructive pulmonary disease (COPD), as in many cases the treatment is inappropriate and could lea
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.
Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as prescribed by offering them educational and motivational tools.